What is a “research peptide”?
A is a messenger molecule: from insulin to GLP-1, medicine has used them for a century. What separates a peptide medicine from a wellness peptide is therefore not the molecule but the road it travelled: controlled synthesis, clinical trials, , pharmacovigilance.
Peptides sold online have travelled none of these stages. They are marketed under the label — a legal formula letting the seller disclaim responsibility for the consequences of human injection.
Does BPC-157 work in humans?
BPC-157 is a synthetic fifteen-amino-acid fragment derived from a protein found in human gastric juice. In rodents it speeds healing of severed tendons, protects the gut lining against anti-inflammatory-induced injury and promotes angiogenesis. These findings are real, reproduced by several teams, and impressive.
They are also exclusively . To date, no published randomised clinical trial has assessed BPC-157 in humans on a healing endpoint. The rat-to-human step fails in the large majority of pharmacology programmes: preclinical enthusiasm is not evidence.
Key point
Do CJC-1295 and ipamorelin raise growth hormone?
These two molecules are s of : they do not replace the hormone, they push the pituitary to release more of it. CJC-1295 mimics GHRH and prolongs stimulation; ipamorelin acts on the ghrelin receptor and triggers shorter pulses, with less effect on cortisol and prolactin than earlier compounds.
Raising GH, and therefore is not a neutral goal. Known effects of GH excess include fluid retention, joint pain, carpal tunnel syndrome and worsened insulin sensitivity. Chronically elevated IGF-1 also raises a cell-proliferation question that nobody has evaluated in the context of prolonged recreational use.
These substances appear on the prohibited list of , including out of competition.
Does TB-500 really repair tissue?
TB-500 is a synthetic fragment of thymosin beta-4, a protein involved in cell migration and tissue repair. It is promoted for muscle and tendon recovery on the basis of animal experiments and veterinary use — notably in racehorses, where doping controls specifically screen for it.
In humans, thymosin beta-4 has been through a few early trials in ophthalmology and cardiology, none transferable to the uses promoted online. One point deserves attention: a molecule stimulating cell migration and angiogenesis works through mechanisms tumours also use. That is not proof of harm, it is an unresolved unknown.
Are these peptides legal in 2026?
In Europe, none of these peptides holds a marketing authorisation, and none is among the substances permitted in food supplements. Selling them for human ingestion or injection is therefore unlawful, whatever the marketing wrapper.
In the United States, the FDA placed BPC-157 in category 2 of its bulk-compounding list — substances raising significant safety risks — which rules out pharmacy compounding. Peptides remain sold through “research chemicals” websites requiring a tick-box declaring non-human use.
For athletes, the WADA list covers GH secretagogues (S2) and growth factors (S2.5), with testing possible at any time of year.
Why is buying peptides online risky?
Even assuming one of these molecules were one day validated, what is bought online today is not that molecule under controlled conditions. Independent analyses of commercial vials converge on three defects.
Three documented risks
- Uncertain identity. Batches contain a different molecule, a mixture, or nothing active at all.
- Unverified dosing. The gap between declared and actual content can run from zero to several times the stated dose.
- Contamination. Residual solvents, heavy metals and s: for an injected product, the latter causes fever, chills and severe inflammatory reactions.
Add the complete absence of pharmacovigilance: if an adverse effect occurs, there is no leaflet, no reporting channel, no counterpart, and no batch traceability.
Frequently asked questions
Is BPC-157 legal in 2026?
Not as a product for human use. BPC-157 holds no marketing authorisation in Europe or the United States. It is neither an authorised medicine nor an authorised food supplement, so selling it for human consumption is unlawful. It circulates only under the “research use only” label, officially destined for the laboratory.
Does BPC-157 work in humans?
Nobody knows. The striking results on tendon, gut and muscle healing come from rat and mouse studies. No published randomised clinical trial of adequate size has assessed BPC-157 in humans. The absence of efficacy evidence comes with an absence of long-term safety data.
What are the risks of peptides bought online?
Three main ones: contamination (bacterial endotoxins, solvents, heavy metals), because products are not made to pharmaceutical good-manufacturing standards; unknown actual dose, sometimes zero, sometimes several times the label; and unverified identity, with independent analyses repeatedly finding molecules other than those advertised.
Do CJC-1295 and ipamorelin raise growth hormone?
They are secretagogues: they stimulate pulsatile pituitary GH release, documented in small, mostly old pharmacological studies. But raising GH and IGF-1 is not trivial: it can promote fluid retention, joint pain and insulin resistance, and raises a theoretical cell-proliferation concern. These substances are banned by the World Anti-Doping Agency, including out of competition.
How is this different from semaglutide, also a peptide?
Regulatory status and level of evidence. Semaglutide went through phase III trials in tens of thousands of participants, holds European and US marketing authorisation, is manufactured under pharmaceutical control and prescribed with medical follow-up. BPC-157 and TB-500 meet none of these conditions.
How are approved peptides different?
The difference in evidence is obvious when reading, in parallel, the dossier on GLP-1 peptides: how GLP-1 works and semaglutide, tirzepatide: what the science says.
Continue in the peptides dossier
Peptides watch — monthly update
This dossier is reviewed monthly. Monitored each month: PubMed-indexed publications on the peptides covered, EMA and FDA communications (alerts, withdrawals, new authorisations), updates to the WADA prohibited list, and ANSM notices on products sold online. Any new data that changes a conclusion is folded into the text and added to the sources.
Last review: · Next review due:
Sources
- U.S. Food and Drug Administration — Certain Bulk Drug Substances for Use in Compounding: category 2 listing (includes BPC-157).
- World Anti-Doping Agency — The Prohibited List: S2 Peptide Hormones, Growth Factors and Related Substances.
- European Medicines Agency — Register of authorised medicines (no marketing authorisation exists for BPC-157, CJC-1295, ipamorelin or TB-500).
- PubMed — published literature on BPC-157 (predominantly rodent and in vitro studies).
- PubMed — published literature on thymosin beta-4 / TB-500 in humans.
- ClinicalTrials.gov — registered interventional trials mentioning BPC-157.
Written and reviewed by Catherine Piault, naturopath · Last reviewed: